Extended Prone Positioning for Intubated ARDS
Extended Prone Positioning for Intubated ARDS: a Randomized Controlled Trial
Assistance Publique - Hôpitaux de Paris
800 participants
Oct 18, 2025
INTERVENTIONAL
Conditions
Summary
Acute respiratory distress syndrome (ARDS) is an acutely induced respiratory failure characterised by the appearance of bilateral alveolar opacities on imaging and hypoxemia(1). Among strategies that have proved beneficial in terms of patient outcome, prone position (PP) is one associated with the greatest impact in terms of reduction in mortality, with PP sessions of 17h on average(2). The benefit of PP is to better homogenize the stress and strain applied to the lung by invasive ventilation. In a multicentric retrospective study involving COVID-19-related intubated ARDS patients, a strategy of extended PP, where PP was maintained for a median duration of 40 hours (h), was associated with increased survival compared to standard PP where each session lasted less than 24h(10). The main objective of this study is to investigate whether extended PP, defined as 40-hour PP sessions, can significantly reduce mortality of patients with invasively ventilated, severe ARDS, at day 28 after inclusion, compared to standard, 16-hour, PP sessions. The primary endpoint is all-cause mortality 28 days after inclusion. The study is a prospective, randomised, open-label, two-group parallel, multicenter trial comparing 40-hour extended PP to 16-hour standard PP in patients with moderate to severe ARDS. After inclusion, patients will be randomised either to standard PP, or extended PP. In the control arm, patients will be turned prone for 16-hour sessions. In the intervention arm, patients will be turned prone for 40h. In both groups, maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions to last 24 hours in the comparator group, and 48 hours in the intervention group. Inclusion criteria will be: severe ARDS, with ARDS defined according to the 2012 Berlin definition; and the severity defined as a PaO2/FiO2 ratio of \<150 mm Hg, with an FiO2 of ≥ 60% persisting for at least 4h after optimization of ventilatory setting. Exclusion criteria will be : PP during the same Intensive care unit ( ICU ) stay and before inclusion, ECMO before PP, arterio-venous ECMO, persistent PaO₂/FiO₂ ratios \<150 mm Hg, with FiO2 ≥ 60% on all arterial blood gases collected over a 24-hour period without prompting study inclusion, spine instability, intracranial pressure \> 20 mmHg, severe brain injury, hemodynamic instability deemed to contraindicate PP by the physician in charge.
Eligibility
Inclusion Criteria10
- Age of 18 years
- Admitted to ICU.
- Under invasive ventilation for a maximum of 5 days.
- Meeting the 2012 Berlin criteria for ARDS
- Protective ventilation at time of inclusion :
- Plateau pressure < 35 cm of H2O at the time of screening
- VT ≤ 8 ml/kg PBW on all nurse's charts before inclusion
- PEEP ≥ 5 cm H2O on all nurse's charts before inclusion
- c. Twice daily blood gas while FiO2 ≥ 60% before inclusion
- PaO2/FiO2 ≤ 150 mmHg with FiO2 ≥ 60% and Spo2 between 92 and 96% after optimization by setting PEEP to 10 mmHg, sedation levels optimization and, if necessary, administration of neuromuscular blockers to ensure patient-ventilator synchrony, with VT ≤ 8 ml/kg PBW and Pplateau < 30 cm H2O.
Exclusion Criteria9
- PP during the same ICU stay and before inclusion, ECMO before PP, arterio-venous ECMO
- persistent PaO₂/FiO₂ ratios <150 mm Hg, with FiO2 ≥ 60% on all arterial blood gases collected over a 24-hour period without this prompting study inclusion
- Spine instability, intracranial pressure > 20 mmHg, severe brain injury, hemodynamic instability deemed to contraindicate PP by the physician in charge
- Home oxygen supplementation
- Care limited to comfort measures only
- Inclusion in another interventional study including mechanically ventilated patients, which intervention concerns PP and for which mortality à D28 or D30 is the main outcome studied.
- Already included in PROSECO
- Pregnancy, subject deprived of freedom, Person under conservartorship, no insurance
- Refusal to participate expressed by the patient or his/her healthcare proxy or a close relative if present
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07126964